Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients

BACKGROUND: Aliskiren was shown to increase adverse events in patients with diabetes and concomitant renin–angiotensin blockade. We aim to investigate the efficacy and safety of aliskiren in patients with diabetes and increased cardiovascular risk or established cardiovascular disease. METHODS: MEDL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Sean L, Roddick, Alistair J, Ayis, Salma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600262/
https://www.ncbi.nlm.nih.gov/pubmed/28844155
http://dx.doi.org/10.1177/1479164117715854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600262/
https://www.ncbi.nlm.nih.gov/pubmed/28844155
http://dx.doi.org/10.1177/1479164117715854

Ejemplares similares